CDSCO's New Drug Licensing Dossier: A Step Towards Uniform Quality Standards

The CDSCO introduced dossier-based guidelines for drug manufacturing licenses, aiming to ensure uniform quality and streamline the application process. Excluding AYUSH drugs, the approach allows a structured assessment of compliance, promoting transparency and efficiency. The initiative follows concerns over drug safety and was endorsed for nationwide implementation by the Drugs Consultative Committee.

The Central Drugs Standard Control Organisation (CDSCO) has rolled out comprehensive guidelines to overhaul the issuance and renewal of drug manufacturing licenses. These dossiers aim to standardize product licenses and maintain quality standards across the board.

The initiative, released last month, introduces a structured checklist that caters to manufacturers' administrative and technical needs, excluding AYUSH drugs, cosmetics, and medical devices. This shift allows regulators to perform structured evaluations rather than relying on fragmented assessments, enhancing transparency and decision-making efficiency.

Following the 61st meeting of the Drugs Consultative Committee, where drug quality and safety concerns were highlighted, the move aligns with nationwide aims for standardization. Designed to assist compliance with the Drugs and Cosmetics Act and Rules, 1945, the system is ready for implementation, promising improved regulatory credibility in India's pharmaceutical landscape.

(With inputs from agencies.)